Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 3,990,000 shares, a growth of 7.3% from the August 15th total of 3,720,000 shares. Approximately 4.1% of the shares of the stock are sold short. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 3.9 days.
Amneal Pharmaceuticals Stock Performance
Amneal Pharmaceuticals stock opened at $2.11 on Thursday. The firm’s 50 day simple moving average is $2.48 and its 200-day simple moving average is $3.00. The company has a market cap of $640.44 million, a P/E ratio of -2.40, a price-to-earnings-growth ratio of 0.14 and a beta of 1.29. The company has a debt-to-equity ratio of 15.38, a current ratio of 1.56 and a quick ratio of 1.03. Amneal Pharmaceuticals has a fifty-two week low of $2.10 and a fifty-two week high of $5.99.
Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) last released its earnings results on Friday, August 5th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.03). The firm had revenue of $559.40 million during the quarter, compared to analysts’ expectations of $534.44 million. Amneal Pharmaceuticals had a positive return on equity of 56.26% and a negative net margin of 6.29%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the business earned $0.23 earnings per share. As a group, equities research analysts predict that Amneal Pharmaceuticals will post 0.65 EPS for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
AMRX has been the topic of several recent research reports. StockNews.com cut shares of Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 24th. TheStreet cut shares of Amneal Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Friday, August 12th. Finally, The Goldman Sachs Group lowered their price objective on shares of Amneal Pharmaceuticals from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Monday, August 8th.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.